The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government. In 2022, IQVIA attempted to acquire Propel, the owner of DeepIntent, though the financial details of the proposed deal remain unknown. However, last summer, the Federal Trade Commission (FTC) intervened and blocked the transaction. Recently, a New York judge upheld the block, and with a touch of inevitability, the pair has decided to halt the deal.
Read the full article: IQVIA, DeepIntent in ‘Incredibly Difficult Moment’ Abandon Merger amid FTC Scrutiny //
Source: https://www.fiercepharma.com/marketing/iqvia-deepintent-incredibly-difficult-moment-abandon-merger-amid-ftc-scrutiny